Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Indolent Non-Hodgkin's Lymphoma
NCT00253630Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- May 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in Indolent Non-Hodgkin Lymphoma (INHL), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate at 3 years and Number of Participants With Adverse Events at 3 years. Started Sep 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT00253630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253630.